Variation in Sex Allocation and Floral Morphology in an Expanding Distylous Plant Hybrid Complex

Premise of research. Sex allocation, the relative energy devoted to producing pollen, ovules, and floral displays, can significantly affect reproductive output and population dynamics. In this study, we investigated floral morphology and gamete production in bisexual, distylous plants from a self-incompatible hybrid complex (Piriqueta cistoides ssp. caroliniana Walter [Arbo]; Turneraceae). Sampling focused on two parent types (C, V) and their stable hybrid derivative (H). Since H morphotypes are heterotic for growth and fruit production, we hypothesized that they would produce larger flowers with more gametes. We also anticipated that plants with long styles (long morphs) would produce less pollen than short morphs, since long-morph pollen is larger. Methodology. Over two consecutive summers, flowers were collected from 1465 individual plants in 28 field populations. Floral parameters were measured digitally, and each flower’s pollen number, ovule number, and stigma-anther separation was quantified under a dissecting microscope. Gamete production (n = 332) and stigma-anther separation (n = 119) were also quantified for plants from a greenhouse accession. Pivotal results. Floral display differed among morphotypes, with H plants producing the largest flowers and C plants displaying the least petal separation. Hybrid morphotypes produced significantly more pollen than parental morphotypes, and pollen quantity was significantly greater for long morphs. Ovule production, however, was greatest for V flowers. Stigma-anther separation differed between years and style morphs (greater for short morphs) but not among morphotypes or within a single season. Conclusions. Differences in pollen production between morphs were not consistent with trade-offs in pollen size and number or selection for increased male function in short morphs. Greater stigma-anther separation in short morphs supported the hypothesis of selection to reduce pollen interference. Enhanced floral display and pollen production followed other heterotic traits observed in H morphotypes. The superior ability of H morphotypes to attract pollinators and sire seeds might partially explain this hybrid zone’s continuing expansion

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score

Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently better in identifying the need for monoclonal antibody infusion throughout each “wave” of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during the coronavirus disease 2019 (COVID-19) pandemic and that the infusion of contemporary monoclonal antibody treatments is associated with a lower risk of hospitalization. Patients and Methods: In this retrospective cohort study, we evaluated the efficacy of monoclonal antibody treatment compared with that of no monoclonal antibody treatment in symptomatic adults who tested positive for SARS-CoV-2 regardless of their risk factors for disease progression or vaccination status during different periods of SARS-CoV-2 variant predominance. The primary outcome was hospitalization within 28 days after COVID-19 diagnosis. The study was conducted on patients with a diagnosis of COVID-19 from November 19, 2020, through May 12, 2022. Results: Of the included 118,936 eligible patients, hospitalization within 28 days of COVID-19 diagnosis occurred in 2.52% (456/18,090) of patients who received monoclonal antibody treatment and 6.98% (7,037/100,846) of patients who did not. Treatment with monoclonal antibody therapies was associated with a lower risk of hospitalization when using stratified data analytics, propensity scoring, and regression and machine learning models with and without adjustments for putative confounding variables, such as advanced age and coexisting medical conditions (eg, relative risk, 0.15; 95% CI, 0.14-0.17). Conclusion: Among patients with mild to moderate COVID-19, including those who have been vaccinated, monoclonal antibody treatment was associated with a lower risk of hospital admission during each wave of the COVID-19 pandemic